The $17 Stock You’ll Wish You Bought (Last Big Wealth Opportunity of the Decade)

SUMMARY

Felix Prehn, an economist and founder of Goat Academy, discusses the risks of passive index fund investing and highlights Adaptive Biotechnologies (ADPT) as a potential high-growth opportunity. He analyzes historical patterns of major stock winners and explains why ADPT may be positioned for significant appreciation based on its business fundamentals and upcoming profitability catalyst.

MAIN POINTS

• Index funds like the S&P 500 are heavily concentrated in just 10 tech stocks, which account for the majority of recent gains. [1:30]
• Major tech companies such as Alphabet and Meta are issuing large amounts of new shares, diluting existing shareholders' value. [6:00]
• Historical analysis shows that many 10x stocks, including Tesla, Netflix, and Apple, traded sideways for years before experiencing explosive growth. [10:00]
• Adaptive Biotechnologies (ADPT) is highlighted for its unique cancer detection technology, strong revenue growth, and approaching profitability, but is noted as a high-risk investment. [15:00]
• Viewers are encouraged to attend a live seminar on the risks of index fund investing and to consider alternative strategies for financial growth. [19:00]

DETAILED ANALYSIS

The presentation begins by challenging the perceived safety of passive index fund investing, specifically targeting the S&P 500. Despite the index's reputation for diversification, it is revealed that just 10 technology companies have been responsible for as much as 72% of recent gains, a figure that fluctuates but remains alarmingly high. This concentration risk means that investors who believe they are broadly exposed to the U.S. economy are, in reality, heavily dependent on the performance of a handful of tech giants.

The situation is further complicated by these companies, such as Alphabet and Meta, issuing substantial new equity—$80 billion in Alphabet's case—resulting in the dilution of existing shareholders' stakes. The analogy of a pizza being sliced into more pieces illustrates how investors' proportional ownership shrinks even as the nominal number of shares remains unchanged.

Felix Prehn references warnings from legendary value investors, noting that the S&P 500 is currently trading at valuations twice its historical average, surpassing even the levels seen during the dot-com bubble of 2000. He cautions that many investors may be unaware of these risks and could find, a decade from now, that their retirement savings have underperformed expectations due to hidden concentration and dilution effects. In response, Prehn is hosting a live seminar to educate investors about the so-called 'index fund trap' and the importance of proactive portfolio management.

The discussion then shifts to the search for outsized returns, or '10x' stocks, by identifying a recurring pattern among historical market winners. Companies like Tesla, Netflix, and Apple are cited as examples that experienced prolonged periods of sideways trading—often two to four years—while their underlying businesses continued to grow. This 'spring compression' effect occurs when a company's fundamentals improve but the stock price remains stagnant, setting the stage for a rapid revaluation once the market recognizes the disconnect.

The key criteria for identifying such opportunities include a flat stock price, evidence of business growth, and the presence of an imminent catalyst.

Adaptive Biotechnologies (ADPT) is presented as a current example fitting this mold. The company specializes in ClonoSEQ, an FDA-cleared diagnostic test capable of detecting a single cancer cell among a million healthy ones, providing a highly sensitive early warning system for blood cancer recurrence. ClonoSEQ is already used by over half of U.S. blood cancer doctors, supported by more than 250 studies, and is covered by insurance for over 300 million Americans.

Despite these achievements, ADPT's market penetration remains below 15%, suggesting significant room for growth. The company's revenue has shown robust increases—102%, 51%, and 35% over the last three quarters—and it is expected to achieve profitability for the first time this year, a milestone that often attracts broader investor interest.

However, Prehn emphasizes the high-risk nature of biotech investing, noting that ADPT's share price is still down 87% from its 2021 peak and that competition and execution risks remain. He clarifies that this is not a buy recommendation but an illustration of the framework for identifying potential breakout stocks. The analysis concludes by urging investors to educate themselves about the limitations of passive investing and to consider attending the upcoming seminar for further insights.

LINKS

• Registration page for the live seminar on the risks of S&P 500 index fund investing.
• Free 30-day trial for the Winston Metals & Stock App.
• Free research report on Adaptive Biotechnologies (ADPT).

KEYWORDS